769.9000 -7.95 (-1.02%)
NSE Jul 24, 2026 15:31 PM
Volume: 242.6K
 

Deven Choksey
Anthem Biosciences has established one of India's most comprehensive integrated CRDMO platforms, offering end-to-end services across the entire pharmaceutical value chain from target identification and lead optimization to preclinical development, clinical trial manufacturing (Phase I, II & III) and commercial manufacturing.
Number of FII/FPI investors increased from 80 to 135 in Jun 2026 qtr.
More from Anthem Biosciences Ltd.
Recommended